Frontiers in endocrinology

Lower starting blood sugar and kidney function link to less favorable body changes after SGLT2 inhibitor treatment in type 2 diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

This study examined body composition changes in patients with type 2 diabetes mellitus (T2DM) treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs).

  • SGLT2i and GLP-1RAs may improve glycemic control in patients with T2DM.
  • These treatments are associated with weight loss.
  • The effects of SGLT2i and GLP-1RAs on the balance between skeletal muscle and fat mass remain unclear.
  • Further research is needed to fully understand treatment-associated changes in body composition.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Aug '24
Kidney health in type 2 diabetes patients using SGLT2 inhibitors versus GLP-1 receptor agonists in regular treatment
top 2% journal
cited by 22 papers
multicenter study
Jan '26
How the order of SGLT2 inhibitors and GLP-1 receptor agonists affects kidney health in type 2 diabetes
top 5% journal
cited by 2 papers
journal article
Mar '26
Kidney health in Japanese people with type 2 diabetes and obesity: comparing two diabetes medicines
top 30% journal
journal article
Dec '25
Metabolic and kidney effects of combined SGLT-2 inhibitor and GLP-1 receptor agonist treatment in type 2 diabetes patients with and without kidney disease
top 20% journal
journal article
Apr '25
How well newer GLP-1RA drugs work when added to SGLT2i treatment in type 2 diabetes
top 2% journal
cited by 25 papers
comparative study
Jan '25
Comparing insulin glargine, GLP-1 receptor drugs, and SGLT-2 inhibitors in veterans with type 2 diabetes
top 5% journal
cited by 2 papers
comparative study

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief